Bioventus Non-GAAP EPS of $0.07 beats by $0.05, revenue of $135.42M beats by $11.46M [Seeking Alpha]
Bioventus Inc. - Class A (BVS)
Company Research
Source: Seeking Alpha
On an organic basis, revenue increased 14.3%, driven by more than 20% growth in Pain Treatments and Surgical Solutions. Bioventus introduced its financial guidance for full-year 2024. The Company expects: Net sales of $520 million to $535 million Adjusted EBITDA* of $89 million to $94 million Non-GAAP EPS* of $0.12 to $0.20 Recommended For You About BVS Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
BVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BVS alerts
High impacting Bioventus Inc. - Class A news events
Weekly update
A roundup of the hottest topics
BVS
News
- Bioventus Inc. (NASDAQ:BVS) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Orthobiologics Market Set to Reach $8.2 Billion by 2030, Viscosupplementation Segment Exhibiting Robust Growth [Yahoo! Finance]Yahoo! Finance
- Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- Bioventus Announces Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswire
- Neuromodulation Market projected to reach USD 15.3 Billion by 2030, growing at a CAGR of 13.0% during the forecast period of 2023-2030 - pronounced by MarketDigits in its recent study [Yahoo! Finance]Yahoo! Finance
BVS
Earnings
- 3/12/24 - Miss
BVS
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- BVS's page on the SEC website